

AUROBAC THERAPEUTICS REINFORCES ITS LEADERSHIP TEAM AND EXPANDS IN THE USA

Lyon (France), July 18, 2024

AUROBAC THERAPEUTICS, a biopharmaceutical company founded by Boehringer Ingelheim, bioMérieux and Evotec, today announced that John P. O'Donnell has joined the company as Chief Development Officer, in the newly formed subsidiary of AUROBAC THERAPEUTICS in the USA.

With over 30 years' experience in pharmaceutical and biotechnology companies, John P. O'Donnell is a distinguished pharmacology and drug metabolism expert. He has authored around 50 publications in peer-reviewed journals and has greatly contributed to the development of several drug candidates, including XACDURO[®], the first targeted antimicrobial approved by the FDA in 2023 for the treatment of *A. baumannii* pneumonia. Most recently, he served as Senior Vice-President, Head of Research at Innoviva Speciality Therapeutics following the acquisition of Entasis Therapeutics where John spent 9 years as Vice-President DMPK, Toxicology and Pharmacology. Prior to Entasis, John headed up pharmacology departments at Pfizer and AstraZeneca within their respective infection portfolios. John received his Bachelor of Science in Biochemistry and Molecular Biology from the University of Massachusetts, Amherst.

This strategic appointment reinforces the leadership team now established with Florence Séjourné as CEO, Martin Everett, Ph.D., as CSO, Johan Frieling, MD, Ph.D., as CMO, Julie Cervesi, Pharm.D., as Head of Business Development, Emeline Gardette, M.Sc., as Head of Chemistry, Manufacturing and Controls (CMC) and Frédérique Sablier-Gallis, Pharm.D., Ph.D., as Head of Project Management and Operations.

"We are thrilled to welcome John to the AUROBAC executive team. With an impressive track record in leading pharmacology and DMPK efforts, John brings a wealth of knowledge and expertise that will be invaluable as we continue to advance our programs to clinical development. Altogether the expansion of our leadership team marks a significant step forward, as we strive to achieve our mission to develop effective treatments targeting bacterial infections, antimicrobial resistance and their consequences in acute hospital settings", said Florence Séjourné, CEO.

About AUROBAC THERAPEUTICS:

AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux. Dedicated to addressing high unmet medical needs associated with infections in acute hospital settings, amidst the growing antimicrobial resistance (AMR) epidemic, AUROBAC is advancing a robust pipeline. This includes ATX101, a potential first-in-class therapeutic targeting the loss of vascular integrity in septic shock, developed in collaboration with Boehringer Ingelheim, and ATX401, an engineered lysin with potent activity against multiple clinically relevant Gram-negative bacteria. Additionally, the company's



unique drug discovery engine aims to identify new precision antimicrobials, as showcased through a collaboration with GENERARE Bioscience.

Contact:

Julie Cervesi, Head of Business Development

contact@aurobac-tx.com

aurobac-tx.com

